Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin in acute type A aortic dissection surgery
NCT04711889Completed
- Sponsor
- Nanjing Medical University
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of ulinastatin in Acute aortic syndrome (AAS) and Type A Aortic Dissection (2 arms), sponsored by Nanjing Medical University. Primary endpoint: Sequential Organ Failure Assessment at 7 days. Started Jan 2021; status: completed.
02
Drugs
ulinastatin
03
Conditions
Acute aortic syndrome (AAS)Type A Aortic Dissection
Beyond the preview
Go deeper on NCT04711889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711889.